benzhydrocodone + acetaminophen

Benzhydrocodone + acetaminophen is a combination oral analgesic comprising benzhydrocodone, a prodrug of the opioid hydrocodone, and acetaminophen, a non-opioid analgesic and antipyretic. Benzhydrocodone is converted in vivo to hydrocodone, a mu-opioid receptor agonist, providing pain relief by altering central nervous system pain signaling. Acetaminophen enhances pain relief through inhibition of prostaglandin synthesis, contributing both analgesic and antipyretic effects. The product is indicated for the short-term treatment (no more than 14 days) of severe, acute pain where alternative therapies are inadequate. Benzhydrocodone + acetaminophen was developed as a potential abuse-deterrent formulation, although it is not classified as abuse-deterrent by the FDA. It is associated with opioid-specific risks (addiction, respiratory depression) and acetaminophen-related hepatotoxicity at high doses[1][3][4][5].

Brand names

Apadaz

Other names

benzhydrocodone and acetaminophenbenzhydrocodone/APAP